Intravitreal crystalline drug delivery for intraocular proliferation diseases

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 1, 2010, Pages 474-481

  Cheng, Lingyun ^a   Hostetler, Karl ^b   Valiaeva, Nadya ^b   Tammewar, Ajay ^a   Freeman, William R ^a   Beadle, James ^b   Bartsch, Dirk Uwe ^a   Aldern, Kathy ^b   Falkenstein, Iryna ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE DERIVATIVE; FLUOROURACIL; GLUCOSE; GUANINE ARABINOSIDE; HEXADECYLOXYPROPYL 5 FLUORO 2' DEOXYURIDINE 5' MONOPHOSPHATE; HEXADECYLOXYPROPYL 5 FLUORO 2' DEOXYURIDINE CYCLIC 3',5' MONOPHOSPHATE; HEXADECYLOXYPROPYL ARABINOFURANOSYLGUANINE 5' MONOPHOSPHATE; PRODRUG; UNCLASSIFIED DRUG; ARABINONUCLEOTIDE; DEOXYURIDINE PHOSPHATE; HEXADECYLOXYPROPYL 5' FLUORO 2' DEOXYURIDINE 5' MONOPHOSPHATE; HEXADECYLOXYPROPYL 5'-FLUORO-2'-DEOXYURIDINE 5'-MONOPHOSPHATE; HEXADECYLOXYPROPYL 5-FLUORO-2'-DEOXYURIDINE CYCLIC-3',5'-MONOPHOSPHATE; HEXADECYLOXYPROPYL-ARABINOFURANOSYLGUANINE 5'-MONOPHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL AGGREGATION; CONTROLLED STUDY; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRORETINOGRAPHY; EYE TOXICITY; FEASIBILITY STUDY; HISTOLOGY; LOW DRUG DOSE; NONHUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; RABBIT; RAT; RETINA; RETINA DETACHMENT; RETINA DISEASE; RETINA INJURY; SLIT LAMP; STRUCTURE ANALYSIS; SUBRETINAL NEOVASCULARIZATION; TONOMETER; VITREORETINOPATHY; VITREOUS BODY; ANIMAL; BROWN NORWAY RAT; CHEMISTRY; CRYSTALLIZATION; DOSE RESPONSE; DRUG EFFECT; FLUORESCENCE ANGIOGRAPHY; INJECTION; OCULOPLETHYSMOGRAPHY; PATHOLOGY; RETINA NEOVASCULARIZATION; SYNTHESIS;

ANIMALS; ARABINONUCLEOTIDES; CRYSTALLIZATION; DEOXYURACIL NUCLEOTIDES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FLUORESCEIN ANGIOGRAPHY; INJECTIONS; OPHTHALMOSCOPY; PRODRUGS; RABBITS; RATS; RATS, INBRED BN; RETINA; RETINAL NEOVASCULARIZATION; TONOMETRY, OCULAR; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 75749153034     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3672     Document Type: Article

References (36)

1. Cheng L, Hostetler KY, Lee J, et al. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest Ophthalmol Vis Sci. 2004;45:4138-4144.
2. Cheng L, Hostetler KY, Chaidhawangul S, et al. Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir. Invest Ophthalmol Vis Sci. 2002;43:515-521.
3. Guembel HO, Krieglsteiner S, Rosenkranz C, Hattenbach LO, Koch FH, Ohrloff C. Complications after implantation of intraocular devices in patients with cytomegalovirus retinitis. Graefes Arch Clin Exp Ophthalmol. 1999;237:824-829.
4. Esmaeli B, Elner SG, Schork MA, Elner VM. Visual outcome and ocular survival after penetrating trauma: a clinicopathologic study. Ophthalmology. 1995;102:393-400.
5. Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol. 2004;137:1105-1115.
6. Pieramici DJ, Sternberg P Jr, Aaberg TM, Sr, et al. A system for classifying mechanical injuries of the eye (globe). The Ocular Trauma Classification Group. Am J Ophthalmol. 1997;123:820-831.
7. Szijarto Z, Gaal V, Kovacs B, Kuhn F. Prognosis of penetrating eye injuries with posterior segment intraocular foreign body. Graefes Arch Clin Exp Ophthalmol. 2008;246:161-165.
8. Waters T, Vollmer L, Sowka J. Proliferative vitreoretinopathy as a late complication of blunt ocular trauma. Optometry. 2008;79:197-202.
9. Iqbal M, Charteris DG, Cooling RJ, Mackintosh GI. Conservative management of double penetrating ocular injuries. Eye. 2000;14:249-251.
10. Charteris DG. Ocular injuries caused by a suction toy. J R Coll Surg Edinb. 1989;34:338-339.
11. Maberley DA, Hollands H, Chuo J, et al. The prevalence of low vision and blindness in Canada. Eye. 2006;20:341-346.
12. Gunnlaugsdottir E, Arnarsson A, Jonasson F. Five-year incidence of visual impairment and blindness in older Icelanders: the Reykjavik Eye Study. Acta Ophthalmol. Published online, February 11, 2009.
13. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol. 1993;115:786-791.
14. Gelfand YA, Linn S, Miller B. The application of the macular photocoagulation study eligibility criteria for laser treatment in age-related macular degeneration. Ophthalmic Surg Lasers. 1997;28:823-827.
15. Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247:1-11.
16. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007;29:1850-1861.
17. Takeda AL, Colquitt J, Clegg AJ, Jones J. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol. 2007;91:1177-1182.
18. Regillo CD, Brown DM, Abraham P, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239-248.
19. Yanase K, Yoshiji H, Ikenaka Y, et al. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep. 2007;17:441-446.
20. Resmini M, Pfleiderer W. Synthesis of arabinonucleoside phosphoramidite building blocks. Helvetica Chim Acta. 1993;76:158-167.
21. Sarthy VP, Brodjian SJ, Dutt K, Kennedy BN, French RP, Crabb JW. Establishment and characterization of a retinal Müller cell line. Invest Ophthalmol Vis Sci. 1998;39:212-216.
22. Bjerke M, Balzarini J, Karlsson A. Reduced levels of mitochondrial DNA increases the toxicity of 9-beta-D-arabinofuranosylguanine (araG). Nucleosides Nucleotides Nucleic Acids. 2008;27:746-749.
23. Dureau P, Bonnel S, Menasche M, Dufier JL, Abitbol M. Quantitative analysis of intravitreal injections in the rat. Curr Eye Res. 2001;22:74-77.
24. Berkowitz BA, Lukaszew RA, Mullins CM, Penn JS. Impaired hyaloidal circulation function and uncoordinated ocular growth patterns in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1998;39:391-396.
25. Cheng L, Hostetler KY, Gardner MF, et al. Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug. Invest Ophthalmol Vis Sci. 1999;40:1487-1495.
26. Cheng L, Hostetler KY, Chaidhawangul S, et al. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. Invest Ophthalmol Vis Sci. 2000;41:1523-1532.
27. Margo CE, Lee A. Fixation of whole eyes: the role of fixative osmolarity in the production of tissue artifact. Graefes Arch Clin Exp Ophthalmol. 1995;233:366-370.
28. Stern WH, Guerin CJ, Erickson PA, Lewis GP, Anderson DH, Fisher SK. Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol. 1983;96:43-51.
29. Leon JA, Britt JM, Hopp RH, Mills RP, Milam AH. Effects of fluorouracil and fluorouridine on protein synthesis in rabbit retina. Invest Ophthalmol Vis Sci. 1990;31:1709-1716.
30. Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RH, Bunce C. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004;111:2240-2245.
31. Cardillo JA, Farah ME, Mitre J, et al. An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Br J Ophthalmol. 2004;88:1201-1205.
32. Maia M, Farah ME, Belfort RN, et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol. 2007;91:1122-1124.
33. Jarus G, Blumenkranz M, Hernandez E, Sossi N. Clearance of intravitreal fluorouracil: normal and aphakic vitrectomized eyes. Ophthalmology. 1985;92:91-96.
34. Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother. 2002;46:2381-2386.
35. Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol. 2003;63:678-681.
36. Cheng L, Hostetler KY, Toyoguchi M, et al. Ganciclovir release rates in vitreous from different formulations of 1-O-hexadecylpropanediol-3-phospho-ganciclovir. J Ocul Pharmacol Ther. 2003;19:161-169.